Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated
to bringing biotech ingenuity to medical dermatology by delivering
differentiated, new therapies to the millions of people living with
chronic skin conditions, today announced its collaboration with
Council of Fashion Designers of America, Inc. (CFDA) fashion
designer Christian Siriano for the Check Your Sweat educational
campaign. Check Your Sweat is designed to raise awareness of
excessive underarm sweating, or primary axillary hyperhidrosis, a
treatable medical condition. Mr. Siriano, recognized around the
world for his inclusive and relatable approach to dressing others,
is fiercely passionate about helping everyone feel confident in
their own skin regardless of shape, size or sweat severity.
Studies have shown that hyperhidrosis often impedes normal daily
activities and can result in occupational, emotional,
psychological, social and physical impairment.1,2 Nearly half of
people living with the condition wait more than 10 years before
seeking out treatment from a physician.1,3 Axillary hyperhidrosis
impacts nearly 10 million people in the United States and causes
them to produce 4-5 times more sweat than the average person,
independent of temperature or activity.1,4 People living with
excessive underarm sweating often develop life-altering workarounds
or coping behaviors such as frequently changing clothes throughout
the day, hiding under bulky or dark-clothing and taking multiple
showers each day.2,5 These activities often impact their social and
professional lives.2,6
“There are people in my life, both personally and
professionally, who have hyperhidrosis, so I know the impact this
condition can have on people’s lives,” said Mr. Siriano. “Though
often minimized, it is a medical condition and one that millions of
people cope with each day. When I learned that clothing choice was
among the top challenges for people with excessive underarm
sweating, I knew I had to get involved. Getting dressed each day
should not be a barrier that prevents people from living life to
the fullest. I’m excited to work with Dermira on the Check Your
Sweat campaign. Together, we’re calling on sufferers to share their
hyperhidrosis stories with us, so we can build a community that
helps people feel confident and supported.”
From October 2 – November 30, Mr. Siriano and Dermira invite
sufferers to submit their ‘sweat stories,’ sweat-free (or totally
sweaty) selfies and their tips for managing hyperhidrosis on
CheckYourSweat.com/share-your-story. The first 50 people who share
their stories will receive a sweat-friendly shirt courtesy of
specialty clothing brands Lawrence Hunt or Thompson Tee. Mr.
Siriano will also be sharing his “Styling for Sweat” tips to help
people with primary axillary hyperhidrosis dress more confidently,
including wearing clothing that allows skin to breathe and looking
for dark-colored shirts or big patterns to minimize the appearance
of sweat. The effort will culminate during Hyperhidrosis Awareness
Month in November, when Mr. Siriano and Dermira will feature
stories from the community to encourage people to speak more openly
about their daily struggles with hyperhidrosis.
“We’re pleased to partner with Mr. Siriano on the Check Your
Sweat campaign to offer educational tools and bring broader
awareness to hyperhidrosis,” said Eugene Bauer, M.D., chief medical
officer at Dermira and a dermatologist. “Mr. Siriano’s outlook on
body positivity aligns closely with Dermira’s mission to help
people uncover renewed confidence through treatments to address
their skin conditions. Together, we can change the sweat
conversation for the better and help empower the hyperhidrosis
community to take steps to learn more about their condition and
manage it with the help of a dermatologist.”
“Primary axillary hyperhidrosis can have a profound impact on a
person’s quality of life and overall well-being, but as many as 49
percent of people who suffer from excessive sweating have never
brought it up with their healthcare professional,”1,3 said Zakiya
Rice, M.D., adjunct clinical professor in the Department of
Dermatology at Emory University School of Medicine and a
board-certified dermatologist practicing at the Dermatology
Associates of Georgia. “I believe Dermira and Mr. Siriano are
taking the right steps to reach and educate people through this
campaign who aren’t familiar with hyperhidrosis and ultimately
encourage them to see their dermatologist for proper medical advice
and treatment.”
For more information on how to manage primary axillary
hyperhidrosis, visit CheckYourSweat.com and follow Check Your Sweat
on Facebook and Instagram.
About HyperhidrosisHyperhidrosis is a condition
of sweating beyond what is physiologically required for normal
thermal regulation and affects an estimated 4.8 percent of the U.S.
population, or approximately 15 million people.1 Of these, 65
percent, or nearly 10 million people, suffer from sweating
localized to the underarms (axillary disease). Studies have
demonstrated that excessive sweating often impedes normal daily
activities and can also result in occupational, emotional,
psychological, social and physical impairment.1,2
About Check Your Sweat Check Your Sweat is a
targeted, patient-centric campaign that seeks to educate, inform
and provide support to hyperhidrosis sufferers. Through these
efforts, Check Your Sweat hopes to elevate awareness about the
medical condition and bring sufferers together to let them know
they are not alone. Visitors to the site can complete a sweat
assessment, which can be used as a discussion guide when talking to
their dermatologist about their sweating. Learn more and complete
the sweat assessment at www.CheckYourSweat.com and follow Check
Your Sweat on Instagram and Facebook.
About DermiraDermira is a biopharmaceutical
company dedicated to bringing biotech ingenuity to medical
dermatology by delivering differentiated, new therapies to the
millions of patients living with chronic skin conditions. Dermira
is committed to understanding the needs of both patients and
physicians and using its insight to identify and develop
leading-edge medical dermatology programs. The company’s approved
treatment, QBREXZA™ (glycopyrronium) cloth, is indicated for
pediatric and adult patients (ages 9 and older) with primary
axillary hyperhidrosis (excessive underarm sweating). Dermira is
also evaluating lebrikizumab in a Phase 2b clinical trial for the
treatment of moderate-to-severe atopic dermatitis (a severe form of
eczema) and has early-stage research programs in other areas of
dermatology. Dermira is headquartered in Menlo Park, Calif. For
more information, please visit http://www.dermira.com. Follow
Dermira on Twitter, LinkedIn and Instagram.
In addition to filings with the Securities and Exchange
Commission (SEC), press releases, public conference calls and
webcasts, Dermira uses its website, LinkedIn page, corporate
Instagram account and corporate Twitter account as channels of
distribution of information about its company, product candidates,
planned financial and other announcements, attendance at upcoming
investor and industry conferences and other matters. Such
information may be deemed material information and Dermira may use
these channels to comply with its disclosure obligations under
Regulation FD. Therefore, investors should monitor Dermira’s
website, LinkedIn page, Instagram and Twitter accounts in addition
to following its SEC filings, news releases, public conference
calls and webcasts.
Dermira Forward-Looking
Statements The information in this news
release contains forward-looking statements and information within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, which are subject to the “safe harbor” created by those
sections. This news release contains forward-looking statements
that involve substantial risks and uncertainties, including
statements with respect to Dermira’s goals of: bringing biotech
ingenuity to medical dermatology by delivering differentiated, new
therapies to the millions of patients living with chronic skin
conditions; raising awareness of primary axillary hyperhidrosis;
building a community that helps people suffering from primary
axillary hyperhidrosis feel confident and supported; helping people
uncover renewed confidence through treatments to address their skin
conditions; and empowering the hyperhidrosis community to take
steps to learn more about their condition and manage it with the
help of a dermatologist. These statements deal with future events
and involve known and unknown risks, uncertainties and other
factors that may cause actual results, performance or achievements
to be materially different from the information expressed or
implied by these forward-looking statements. Factors that could
cause actual results to differ materially include risks and
uncertainties such as those relating to Dermira’s dependence on
third-party clinical research organizations, manufacturers and
suppliers; Dermira’s ability to attract and retain key employees;
Dermira’s ability to obtain necessary additional capital; market
acceptance of Dermira’s potential products; Dermira’s ability to
develop and maintain collaborations and license products and
intellectual property; the impact of competitive products and
therapies, including generics and biosimilars; Dermira’s ability to
manage the growth and complexity of its organization; Dermira’s
ability to maintain, protect and enhance its intellectual property;
the design, implementation and outcomes of Dermira’s clinical
trials; the outcomes of Dermira’s future meetings with regulatory
agencies; and Dermira’s ability to continue to stay in compliance
with applicable laws and regulations. You should refer to the
section entitled “Risk Factors” set forth in Dermira’s Annual
Report on Form 10-K, Dermira’s Quarterly Reports on Form 10-Q and
other filings Dermira makes with the SEC from time
to time for a discussion of important factors that may cause actual
results to differ materially from those expressed or implied by
Dermira’s forward-looking statements. Furthermore, such
forward-looking statements speak only as of the date of this news
release. Dermira undertakes no obligation to publicly
update any forward-looking statements or reasons why actual results
might differ, whether as a result of new information, future events
or otherwise, except as required by law.
Contacts:
Media:Erica JeffersonVice President, Corporate
Communications650-421-7216media@dermira.com
Erin MurphyDirector, Corporate
Communications650-422-7746erin.murphy@dermira.com
Investors:Ian Clements, Ph.D.Vice President, Investor
Relations650-422-7753investor@dermira.com
References:1 Doolittle, J., Walker, P., Mills,
T., & Thurston, J. (October 15, 2016). Hyperhidrosis: an update
on prevalence and severity in the United States. Accessed October
04, 2017, from
https://link.springer.com/content/pdf/10.1007%2Fs00403-016-1697-9.pdf.2
Kamudoni, et al. The impact of hyperhidrosis on patients’ daily
life and quality of life: a qualitative investigation. Health and
Quality of Life Outcomes, 15(1). 2017.3 Glaser, D. A., Ballard, A.
M., Hunt, N. L., Pieretti, L. J., & Pariser, D. (2016).
Prevalence of Multifocal Primary Hyperhidrosis and Symptom Severity
Over Time: Results of a Targeted Survey. American Society for
Dermatologic Surgery. Accessed on February 28, 2018, from
https://www.ncbi.nlm.nih.gov/pubmed/27879523.4 Hund, M. (2002).
Definition of Axillary Hyperhidrosis by Gravimetric Assessment.
Arch Dermatology, vol. 138, pp. 539-541.5 International
Hyperhidrosis Society. (2016). Diagnosing Hyperhidrosis. Accessed
October 04, 2017 from
https://www.sweathelp.org/home/diagnosing-hyperhidrosis.html.6
Bahar, Rayeheh, et al. The prevalence of anxiety and depression in
patients with or without hyperhidrosis (HH). Journal of the
American Academy of Dermatology, vol. 75, no. 6, 2016, pp.
1126–1133., doi:10.1016/j.jaad.2016.07.001.
Photos accompanying this announcement are available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/7002c77b-c379-4e15-9d8f-71b3112a8f2e
http://www.globenewswire.com/NewsRoom/AttachmentNg/389982d3-2b71-4bf5-98ae-718678ff552d
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Jul 2023 to Jul 2024